Does Blue Cross of Idaho Cover Farxiga?

How Blue Cross of Idaho Handles Farxiga on Its Formulary

Blue Cross of Idaho maintains multiple formulary lists depending on plan type: individual/family, employer-sponsored group, and Medicare Advantage. Farxiga (dapagliflozin 5 mg and 10 mg tablets) appears on most of these formularies, but the tier and cost-sharing structure vary by product line.

Commercial Plan Formulary Placement

On the majority of Blue Cross of Idaho commercial plans, Farxiga sits on the preferred brand tier (Tier 2) or the non-preferred brand tier (Tier 3). Tier 2 placement generally translates to a fixed copay between $35 and $60 per 30-day supply. Tier 3 placement pushes that copay higher, typically $60 to $90, or shifts to a coinsurance model where the member pays 20% to 30% of the drug's list price after the deductible. The wholesale acquisition cost (WAC) for Farxiga 10 mg runs approximately $570 to $610 per month [1].

Medicare Advantage and Part D

Blue Cross of Idaho's Medicare Advantage plans cover Farxiga under Part D prescription drug benefits. Beneficiaries in the initial coverage phase may pay a $47 to $100 copay depending on their specific plan. Once members enter the coverage gap (the so-called "donut hole"), the Inflation Reduction Act's $2,000 annual out-of-pocket cap, fully effective since 2025, limits total Part D spending regardless of Farxiga's list price [2]. This cap has made SGLT2 inhibitors significantly more accessible for Medicare enrollees across Idaho.

Prior Authorization Requirements for Farxiga

Most Blue Cross of Idaho plans require prior authorization (PA) before dispensing Farxiga. The PA process exists because SGLT2 inhibitors cost substantially more than generic first-line agents like metformin (approximately $4 to $15 per month). Understanding what the insurer needs before approving coverage prevents prescription delays.

What the PA Typically Requires

Blue Cross of Idaho's utilization management criteria generally ask the prescribing clinician to confirm three things. First, the patient has a documented diagnosis of type 2 diabetes mellitus, symptomatic heart failure (NYHA class II through IV), or chronic kidney disease with an eGFR of 25 to 75 mL/min/1.73 m². Second, the patient has tried and either failed, shown intolerance to, or has a contraindication to metformin (for diabetes indications). Third, the prescriber is requesting a dose consistent with FDA labeling: 5 mg or 10 mg once daily.

Step Therapy Protocols

Step therapy is a related but distinct requirement. Blue Cross of Idaho frequently mandates that patients with type 2 diabetes demonstrate an adequate trial of metformin (typically 90 days at a dose of 1,500 mg/day or higher) before the plan will approve Farxiga. The American Diabetes Association's 2024 Standards of Care support metformin as a first-line pharmacologic therapy for most patients with type 2 diabetes, though the ADA also notes that SGLT2 inhibitors should be considered regardless of A1C in patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or CKD [3]. If your patient falls into one of these high-risk categories, many insurers, including Blue Cross of Idaho, will waive the step therapy requirement when the prescriber documents the clinical rationale.

How Long Approval Takes

PA decisions from Blue Cross of Idaho are typically returned within 48 to 72 hours for standard requests. Urgent requests tied to hospital discharge or acute clinical need may be processed within 24 hours. If the initial PA is denied, members and prescribers have the right to file an appeal, and Idaho's Department of Insurance mandates that insurers complete internal appeals within 30 days for non-urgent cases.

Why Insurers Cover Farxiga: The Clinical Evidence

Payer coverage decisions for Farxiga are grounded in a strong base of randomized controlled trial data across three FDA-approved indications. Blue Cross of Idaho, like most commercial insurers, evaluates this evidence through its pharmacy and therapeutics (P&T) committee when placing drugs on the formulary.

Type 2 Diabetes: DECLARE-TIMI 58

The DECLARE-TIMI 58 trial (N=17,160) randomized patients with type 2 diabetes who had or were at risk for ASCVD to dapagliflozin 10 mg or placebo. Over a median follow-up of 4.2 years, dapagliflozin reduced the rate of cardiovascular death or hospitalization for heart failure by 17% (HR 0.83, 95% CI 0.73 to 0.95, P=0.005) [4]. A1C reductions averaged 0.42% more than placebo at 12 months. The trial did not show a statistically significant reduction in major adverse cardiovascular events (MACE) in the overall population, but the heart-failure signal was strong enough to drive a supplemental FDA indication.

Heart Failure: DAPA-HF

DAPA-HF (N=4,744) tested dapagliflozin 10 mg in patients with heart failure and reduced ejection fraction (EF ≤40%), regardless of diabetes status. The primary composite endpoint of worsening heart failure or cardiovascular death occurred in 16.3% of the dapagliflozin group versus 21.2% in the placebo group (HR 0.74, 95% CI 0.65 to 0.85, P<0.001) [5]. The number needed to treat (NNT) was 21 over a median of 18.2 months. This trial changed clinical practice and prompted the American College of Cardiology to include SGLT2 inhibitors in the four-pillar heart failure treatment framework.

Chronic Kidney Disease: DAPA-CKD

DAPA-CKD (N=4,304) enrolled patients with CKD and a urine albumin-to-creatinine ratio of 200 to 5,000 mg/g, with or without diabetes. The trial was stopped early for overwhelming efficacy: dapagliflozin reduced the primary composite of sustained ≥50% decline in eGFR, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) [6]. The 2024 KDIGO guidelines now recommend SGLT2 inhibitors as a standard-of-care therapy for patients with CKD and albuminuria, a recommendation that has pushed most major insurers to cover Farxiga for this indication [7].

Dr. Hiddo Heerspink, lead DAPA-CKD investigator and professor of clinical pharmacology at the University Medical Center Groningen, stated: "The magnitude of kidney protection we saw with dapagliflozin is unlike anything we've achieved with a single agent in the past two decades of nephrology trials" [6].

How to Reduce Your Out-of-Pocket Cost with Blue Cross of Idaho

Even with formulary coverage, the brand-tier copay for Farxiga can strain monthly budgets. Several strategies can bring the net cost down significantly.

AstraZeneca's Savings Card

AstraZeneca offers a manufacturer copay assistance card for commercially insured patients (not valid for government-funded plans such as Medicare, Medicaid, or TRICARE). Eligible patients can pay as little as $0 per month, with savings up to $450 per fill. The card is renewable annually and can be activated through AstraZeneca's patient support website [1].

Formulary Exception Requests

If your Blue Cross of Idaho plan places Farxiga on a non-preferred tier, your prescriber can file a formulary tier exception request. This involves documenting that lower-tier alternatives (such as empagliflozin/Jardiance) are not clinically appropriate due to contraindications, prior adverse reactions, or therapeutic failure. If granted, the plan reclassifies Farxiga to a lower-cost tier for that member.

Specialty Pharmacy and Mail-Order Savings

Blue Cross of Idaho contracts with preferred specialty and mail-order pharmacies. Members who fill a 90-day supply through mail order can sometimes reduce the per-fill copay by 10% to 25% compared to three consecutive 30-day retail fills. Check your plan's pharmacy network directory or call the member services number on your insurance card to confirm which mail-order pharmacy yields the lowest cost.

Farxiga Dosing and What Your Plan Covers

The FDA-approved dosing for dapagliflozin is 5 mg or 10 mg once daily, taken in the morning with or without food. Blue Cross of Idaho covers both strengths, though PA criteria may specify the appropriate dose based on indication.

Dose by Indication

For type 2 diabetes, the recommended starting dose is 5 mg daily, with an option to increase to 10 mg for patients who need additional glycemic control and tolerate the lower dose. For heart failure and CKD, the recommended dose is 10 mg daily, which is the dose studied in DAPA-HF and DAPA-CKD [8]. Prescribers requesting 10 mg for diabetes patients should document the clinical rationale on the PA form.

Renal Dosing Considerations

Farxiga's glycemic efficacy depends on renal glucose filtration, which diminishes at lower eGFR values. The FDA updated Farxiga's label in 2021 to allow initiation in patients with eGFR as low as 25 mL/min/1.73 m² when used for CKD or heart failure, reflecting the DAPA-CKD data [8]. Blue Cross of Idaho's PA criteria mirror this labeling. Clinicians should include the patient's most recent eGFR on the authorization request.

Comparing Farxiga to Other SGLT2 Inhibitors on Blue Cross of Idaho

Farxiga is not the only SGLT2 inhibitor available. Understanding how Blue Cross of Idaho positions its competitors helps prescribers and patients choose the most cost-effective option.

Jardiance (Empagliflozin)

Jardiance is often placed on the same formulary tier as Farxiga, and in some Blue Cross of Idaho plan years, one may be preferred over the other. The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% reduction in cardiovascular death with empagliflozin versus placebo in patients with type 2 diabetes and established cardiovascular disease (HR 0.62, 95% CI 0.49 to 0.77, P<0.001) [9]. Unlike Farxiga, Jardiance does not yet carry an FDA indication for CKD independent of diabetes, though the EMPA-KIDNEY trial (N=6,609) showed a 28% reduction in the composite kidney endpoint [10].

Invokana (Canagliflozin)

Canagliflozin appeared on the market first but has faced formulary pressures due to safety signals. The CANVAS trial identified a roughly twofold increased risk of lower-limb amputation with canagliflozin (6.3 vs 3.4 per 1,000 patient-years), a finding not replicated with dapagliflozin or empagliflozin [11]. Many P&T committees, including those advising Blue Cross of Idaho, now position canagliflozin behind dapagliflozin and empagliflozin on the formulary.

Generic Availability

No generic version of dapagliflozin is currently available in the United States. AstraZeneca's composition-of-matter patent for Farxiga is expected to provide market exclusivity through 2026. Generic entry, if it occurs, could reduce the cost by 80% to 90% based on typical brand-to-generic price dynamics in the SGLT2 class.

Safety Profile and Monitoring

SGLT2 inhibitors share a class-level safety profile that prescribers and patients should understand. Blue Cross of Idaho's PA criteria do not typically restrict coverage based on these risks, but they are relevant to clinical decision-making.

Common Adverse Effects

Genital mycotic infections occur in approximately 5% to 8% of women and 3% to 5% of men taking SGLT2 inhibitors, driven by glucosuria [4]. Urinary tract infections occur at a modestly higher rate than placebo (4.7% vs 3.5% in DECLARE-TIMI 58). Volume depletion and orthostatic hypotension can occur, particularly in patients taking loop diuretics or those over age 75.

Diabetic Ketoacidosis

Euglycemic diabetic ketoacidosis (DKA) is a rare but serious risk, reported in approximately 0.1% to 0.3% of patients in clinical trials [4]. The FDA requires a boxed warning about DKA on all SGLT2 inhibitor labels. Patients should be counseled to hold Farxiga before major surgery (at least 3 days prior) and during acute illness with reduced oral intake.

Fournier Gangrene

Post-marketing surveillance has identified a very rare association between SGLT2 inhibitors and Fournier gangrene (necrotizing fasciitis of the perineum). The FDA issued a safety communication in 2018 after identifying 55 cases across all SGLT2 inhibitors over a 5-year period [12]. The absolute risk remains extremely low, but patients should seek immediate medical attention for severe perineal pain, tenderness, erythema, or swelling.

What to Do if Blue Cross of Idaho Denies Farxiga Coverage

Coverage denials happen. They are not the final word. A structured appeals process can reverse many initial denials.

Internal Appeal Steps

Contact Blue Cross of Idaho's member services line (printed on your insurance card) within 180 days of the denial letter. Request an internal appeal and ask your prescriber to submit a letter of medical necessity. The letter should reference the patient's specific diagnosis, relevant lab values (A1C, eGFR, UACR, ejection fraction), prior medication trials and outcomes, and the clinical trial evidence supporting Farxiga for that indication. The 2024 ADA Standards of Care and 2024 KDIGO guidelines are strong supporting documents to attach [3][7].

External Review

If the internal appeal is denied, Idaho law (Idaho Code § 41-5903) entitles members to an independent external review conducted by a third-party physician reviewer. The member must file this request within four months of the final internal denial. The external reviewer's decision is binding on Blue Cross of Idaho.

Alternative Coverage Pathways

If all appeals fail, patients may access Farxiga through AstraZeneca's patient assistance program (AZ&Me), which provides the medication at no cost to uninsured or underinsured patients meeting income eligibility criteria (generally household income at or below 400% of the federal poverty level). Prescribers can submit applications through AstraZeneca's provider portal.